TG Therapeutics lifts 2026 revenue outlook to about $1 billion after Q3
TG Therapeutics reported Q3 2026 revenue of $259.9 million, including $232.6 million in US BRIUMVI sales, and raised full-year guidance from about $950 million.
Last updated
Not investment advice. Read the disclaimer.
TG Therapeutics raised its full-year 2026 revenue guidance on November 9 after reporting third-quarter results, according to the company's release. The multiple sclerosis drugmaker now expects total global revenue of about $1 billion for 2026, up from about $950 million previously.
Third-quarter results
- Total global revenue: $259.9 million.
- BRIUMVI US net product revenue: $232.6 million, about 52% higher than a year earlier.
- Share buybacks: about $100 million of shares repurchased during the quarter, the company said.
StreetInsider reported that quarterly earnings per share of $0.35 came in $0.02 below the analyst estimate of $0.37, while revenue beat the consensus estimate of $245.47 million.
Updated 2026 guidance
TG Therapeutics' new targets for 2026:
- Total global revenue of about $1 billion, up from about $950 million.
- BRIUMVI US net product revenue of about $915 million to $920 million, up from $890 million to $905 million.
- Operating expenses (R&D and SG&A, excluding non-cash compensation) of about $450 million to $500 million, unchanged. This includes subcutaneous BRIUMVI manufacturing costs and start-up costs for a second manufacturer.
What management expects next
"With solid third-quarter performance and a strong fourth quarter anticipated, we are on track to exceed $1 billion in global revenue in 2026, less than four years after launching BRIUMVI," said chairman and CEO Michael S. Weiss.
Weiss listed several catalysts for the next 18 to 24 months:
- Pivotal Phase 3 results for subcutaneous BRIUMVI, expected around year-end 2026 or early 2027.
- A possible launch of a simplified IV starting regimen in mid-2027, following the Phase 3 ENHANCE trial.
- A possible launch of subcutaneous BRIUMVI in 2028.
The company also pointed to data presented at MSToronto2026, including seven-year follow-up from its ULTIMATE I and II Phase 3 trials.
This article is for information only and is not investment advice. Company guidance is a forecast and may change.
More in Companies and Earnings.